Nuestros recursos

ObvioHealth welcomes sales veteran Richard Watkins as CRO to guide the company’s shift to enterprise software. His proven leadership in SaaS and healthcare will help expand ObvioGo® 2.0’s impact on clinical trials worldwide.

ObvioHealth announces the appointment of seasoned healthcare executive Nicholas Campbell to its Board of Directors. Campbell brings expertise to accelerate digital innovation and advance clinical trial solutions.

VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration. ​

The upgraded platform gives sponsors the ability to mix hybrid and virtual trial designs within one study, easily tailoring workflows to sites, locations, and study populations.

The FDA and OHRP have released new draft guidance providing recommendations for making the informed consent process as clear and comprehensive as possible for participants. Here's what you need to know.

ObvioHealth’s innovative study design will allow Ready. Set. Food! to follow babies in the real world for two years.

In this webinar, our expert panelists—including a participant—explore the Mi-Helper clinical trial as a case study, reviewing the challenges associated with conducting medical device studies remotely, and how collaboration and iteration can help to identify and mitigate risks from the outset. Download the webinar summary by filling out the form below.

Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.